难治性肾病综合征的病因及治疗研究进展被引量：37

下载PDF

导出

摘要随着人类生活水平和健康意识的提高,各种慢性肾脏疾病（chronickidney diseases,CKD）的发病率也在不断上升,其发病率已达10%左右。临床上由于大量蛋白尿是导致肾功能恶化的独立危险因素,因此肾病综合征（NS）无论是原发性还是继发性,若大量蛋白尿得不到有效控制,将导致肾组织进行性纤维化,继而逐渐发展至终末期肾病。难治性NS（refractory ne-phritic syndrome,RNS）通常指常复发型、激素依赖、激素抵抗型或激素不耐受、激素使用禁忌的NS,

作者郝静袁伟杰

机构地区上海交通大学附属第一人民医院肾内科

出处《中国中西医结合肾病杂志》 2013年第6期553-555,共3页 Chinese Journal of Integrated Traditional and Western Nephrology

关键词难治性肾病综合征 diseases 大量蛋白尿治疗病因慢性肾脏疾病独立危险因素激素依赖

分类号 R692.3 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献17

1Hodson EM, Craig JC. Therapies for steroid - resistant nephrotic syndrome. Pediatr Nephro1,2008,23 (9) : 1391 - 1394.
2<环孢素A在肾内科的应用>专家协作组.环孢素A治疗肾小球疾病的应用共识[J].中华肾脏病杂志,2005,21(9):556-557. 被引量：74
3Saito T. Refractory nephrotic syndrome. Nippon Rinsho, 2004,62 (10) :1794.
4Kaneko K,Tuchiya K. Thl/Th2 balance in childhood idiopathic nephritic syndrome. Clin Nephrol,2002,58 (6) :393 -397.
5Kim SD, Kim IS, Lee BC, et al. Apolipoprotein E polymorphism and clinical course in childhood nephritic syndrome. Pediatr Nephro1,2003,18 ( 3 ) :230 - 233.
6Komatsada A, Wakui H, Maki N, et al. Analysis of mutations in alpha - actinin 4 and podocin genes of patients with chronic renal failure dui to spodradie focal segmental glomerulosclerosis. Ren Fail,2003,25 ( 1 ) : 87 - 93.
7Oh J, Beckman J, Bloeh J, et al. Stimulation of the calcium - sensing receptor stabilizes the podoeyte eytoskeleton, improves cell survival, and reduces toxin -induced glomeruloselerosis. Kidney Int, 2011 80 (5) : 483 - 492.
8Choudhry S, Bagga A, Haris P, et al. Efficacy and safe of tacroli- mos versus cyclooporin in childrin with steroid - resistant ne- phrotic syndrome:A randomezed controlled triM. American Joum- al of Kidney disease,2009,53 (4) :760- 769.
9Novak L, Frank R, Vento S, et al. Efficacy of mycophenolate mof- etil in pediatric patients with steroid - dependent nephrotic syn- drcme. Pediatr Nephrol,2005,20 (9) : 1265 - 1268.
10Gulati S, Prasad N, Sharma RK, et al. Taerolimus : a new thera- py for steroid - resistant nephrotic syndrome in children. Neph- rol Dial Transplant,2008,23 (7) :910 - 913.

二级参考文献21

1陆福明 ,丁小强 ,陈楠 ,钱家麒 ,徐琴君 ,袁伟杰 ,梅长林 ,徐玉兰 ,侯凡凡 ,林善锬 .吗替麦考酚酯治疗原发性肾病综合征的前瞻性多中心临床研究[J].中华肾脏病杂志,2004,20(4):238-241. 被引量：35
2吗替麦考酚酯在肾内科应用专家共识组,赵明辉,陆福明.吗替麦考酚酯在肾内科应用专家共识2006年第四次修订[J].中华内科杂志,2006,45(11):965-966. 被引量：16
3Stratta P, Segoloni GP, Canavese C, et al. Incidence of biopsy-proven primary glomerulonephritis in an Italian province. Am J Kidney Dis, 1996, 27: 631-639.
4Simon P, Ramee MP, Autuly V, et al. Epidemiology of primary glomerular diseases in a French region. Variations according to period and age. Kidney Int, 1994, 46: 1192- 1198.
5Harmankaya O, Basttirk T, Oztiirk Y, et al. Effect of acetylsalicylic acid and dipyridamole in primary membranoproliferative glomerulonephritis type Ⅰ. Int Urol Nephrol, 2001, 33: 583-587.
6Karim MY, Alba P, Cuadrado MJ, et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology(Oxford), 2002, 41: 876- 882.
7Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular disease. Kidney Int, 2002, 61: 1089-1114.
8Grcevska L, Polenakovic M. Mycophenolate mofetil in the treatment of glomerular diseases. Prilozi, 2007, 28: 57-68.
9Sahin GM, Sahin S, Kantarci G, et al. Mycophenolate mofetil treatment for therapy-resistant glomerulopathies. Nephrology (Carlton), 2007, 12: 285-288.
10Jones G, Juszczak M, Kingdom E, et al. Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant, 2004, 19: 3160-3164.